They Just Don't Get...
Health Care: Drugs
Depomed Inc. (DEPO: NASDAQ)
$5.01 0.01 | 0.20%
06/04/12 - 12:14 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 132.97M | 80.76M | 57.73M | 34.84M |
| Cost of Sales | 5.12M | 7.66M | 4.45M | 4.62M |
| Gross Operating Profit | 127.85M | 73.11M | 53.28M | 30.22M |
| Selling, General, and Administrative Expenses | 54.20M | 17.51M | 16.66M | 26.40M |
| Research & Development | 15.19M | 20.11M | 34.30M | 27.27M |
| Operating Income before D & A (EBITDA) | 31.12M | 4.06M | -21.26M | -23.45M |
| Depreciation & Amortization | 420.00K | 439.00K | 808.00K | 1.15M |
| Interest Income | 557.00K | 839.00K | 1.05M | 2.35M |
| Other Income - Net | 0.00 | 0.00 | 0.00 | 7.50M |
| Special Income / Charges | 40.00M | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 71.26M | 4.46M | -21.02M | -14.75M |
| Interest Expense | 133.00K | 572.00K | 1.00M | 555.00K |
| Pre-Tax Income | 71.12M | 3.89M | -22.02M | -15.30M |
| Income Taxes | 396.00K | -4.00K | -15.00K | 1.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 70.73M | 3.90M | -22.01M | -15.30M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 70.73M | 3.90M | -22.01M | -15.30M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 70.73M | 3.90M | -22.01M | -15.30M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
30.73M | 3.90M | -22.01M | -15.30M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 70.73M | 3.90M | -22.01M | -15.84M |
| Basic EPS from Continuing Ops. | 1.30 | 0.07 | -0.43 | -0.32 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 1.30 | 0.07 | -0.43 | -0.32 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 1.30 | 0.07 | -0.43 | -0.32 |
| Basic Normalized Net Income/Share | 0.56 | 0.07 | -0.43 | -0.32 |
| EPS fr Continuing Ops. | 1.26 | 0.07 | -0.43 | -0.32 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 1.26 | 0.07 | -0.43 | -0.32 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 1.26 | 0.07 | -0.43 | -0.32 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.55 | 0.07 | -0.43 | -0.32 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
- Usergbwineman Portfolio 1
- UserLTR7181 Portfolio 1
- Userfrankie'spicks
Latest DEPO Headlines from TheStreet
- Stocks Under $10: Healthcare Name on Sale
05.17.12 | 07:05 am - Depomed: After-Hours Trading 02.03.12 | 05:02 pm
- Depomed Stock Hits New 52-Week Low (DEPO) 10.18.11 | 10:10 am
- Depomed Stock Gaps Down On Today's Open (DEPO) 10.14.11 | 09:10 am
- 7 Stocks to Watch: Google, Apple 10.14.11 | 07:10 am
- Google, Depomed: After-Hours Trading 10.13.11 | 05:10 pm
- Acadia Pharmaceuticals: Investing With No Safety Net 06.24.11 | 10:06 am
- Biotech Stock Mailbag: Star Scientific 03.18.11 | 07:03 am
- 5 Stocks to Watch: Sanmina, UBS 03.17.11 | 07:03 am
- Guess?, DepoMed: After-Hours Trading 03.16.11 | 05:03 pm
Press Releases for DEPO
- Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf - PR Newswire 05.29.12 | 08:05 am
- Depomed To Present At Jefferies 2012 Global Health Care Conference - PR Newswire 05.25.12 | 08:05 am
- Depomed To Present At Bank Of America Merrill Lynch 2012 Health Care Conference - PR Newswire 05.10.12 | 08:05 am
- New 60,000 Square Foot Lease At The Pacific Research Center Signed By Biomed Realty And Depomed - PR Newswire 04.09.12 | 04:04 pm
- Santarus And Depomed Announce Settlement With Lupin Of GLUMETZA Patent Litigation - Business Wire 02.22.12 | 04:02 pm
- Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products - Business Wire 08.22.11 | 05:08 am
- Ironwood Pharmaceuticals And Depomed Announce Collaboration, Research And License Agreement - Business Wire 07.27.11 | 04:07 pm
- Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets - Business Wire 01.05.11 | 04:01 am
- New Clinical Study Shows Patients With Type 2 Diabetes May Be Able To Tolerate Higher Doses Of Metformin Using GLUMETZA - PR Newswire 06.28.10 | 08:06 am
- Depomed To Present At The 9th Annual JMP Securities Research Conference - Business Wire 05.04.10 | 08:05 am
Partner Headlines for DEPO
- New Constructs' Most Attractive Stocks for June - Benzinga 06.04.12 | 09:06 am
- The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - Zacks 05.18.12 | 09:05 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows - Seeking Alpha 02.03.12 | 07:02 pm
- Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck - Benzinga 02.03.12 | 04:02 pm
- Depomed Receives Notice of Paragraph IV Certification Against Patents for Gralise - Benzinga 01.23.12 | 04:01 pm
- BMS Drug Deemed Too Costly: Weekly Round-Up Of Biotech Failures And Mishaps - Seeking Alpha 10.16.11 | 08:10 am
- UPDATE: Zacks Upgrades DepoMed from Neutral to Outperform - Benzinga 08.10.11 | 09:08 am
- 5 Highly Profitable Stocks Undervalued by EPS Trends - Seeking Alpha 07.11.11 | 06:07 am
- Contrarian Ideas: 25 High Growth Stocks With Significant Short Selling - Seeking Alpha 06.06.11 | 08:06 am
